Lilly ICOS LLC announces Pivotal Clinical Trial to Evaluate
the Use of Tadalafil for Pulmonary Arterial Hypertension
Lilly
ICOS LLC, a joint venture between ICOS Corporation and Eli Lilly and Company,
plans to conduct a pivotal clinical trial to evaluate the potential benefits
and safety of oral tadalafil administered once daily for the treatment
of pulmonary arterial hypertension (PAH). The clinical trial will be a
randomized, multicenter, double blind study to be initiated this summer
throughout North America and Europe.
Tadalafil is an inhibitor
of the PDE5 enzyme. PDE5 is one of the significant phosphodiesterases
in the pulmonary vasculature. Inhibition of PDE5 maintains high cyclic
guanosine monophosphate (cGMP) levels which in turn may potentiate nitric
oxide-mediated pulmonary vasodilation and antiproliferative effects in
patients with PAH.
For more information
on the planned clinical trial in PAH, contact Mari Maurer (425-415-5302)
or Dr. Lyn Frumkin (425-415-5571) at ICOS Corporation.
Predix Pharmaceuticals Initiates Phase I
Clinical Trial of 5-HT2B Receptor Antagonist for Pulmonary Hypertension
WOBURN, Mass. &
RAMAT GAN, Israel--(BUSINESS WIRE)--May 3, 2005--Predix Pharmaceuticals,
a drug discovery and development company, today announced the initiation
of Phase I first in human studies with PRX-08066, its highly selective,
proprietary 5-HT2B receptor antagonist for the treatment of pulmonary
hypertension (PH) and hypoxia-induced PH syndromes caused by chronic obstructive
pulmonary disease and mountain sickness. This drug candidate is the third
compound Predix has discovered and advanced into clinical development
in less than three years.
Pulmonary
Hypertension - A Patient's Survival Guide The premiere information resource
for people dealing with PH -- they have ARRIVED and are ready to
ship!!!
The author, a PH patient herself,
knows what it is like to live with the disease. She talked to many
other patients, doctors, and researchers while writing the Survival
Guide. Dr. Ronald J. Oudiz and a team of physicians with a deep
knowledge of PH edited the book for accuracy.
New edition contains a chart
of 15 drugs used to treat PH; results of recent
clinical trials;
in-depth discussion of PH secondary to other diseases
or conditions;
a new chapter on what to eat if you have PH; and much, much more!
The California PH Forum offers support and medical updates for patients, their families, friends, and medical professionals interested in Pulmonary Arterial Hypertension. It is presented in the years in between the Pulmonary Hypertension Association's biennial international conferences.
The PH Forum sessions will feature Physicians, Nurses, and other Medical Professionals specializing in PAH, and assisted by knowledgeable patients who will share their experiences and hope with you.
On
July 4, 1999 our good friend Kipp Palmer passed away from complications
due to Primary Pulmonary Hypertension. Not only was Kipp a great golfer,
but he was a fighter who, in the end, couldn't prevail over PPH. Help
us remember Kipp on June 24th while contributing to the good cause
of PPH cure research.
An athletic and
extroverted teen, Justin was diagnosed two years ago with primary pulmonary
hypertension, a condition that will require either a double lung transplant
or a heart and lung transplant, his doctors say.
Myogen's
Ambrisentan granted orphan drug designation by Europeans
Myogen today
announced that the Commission of the European Communities, with a
favorable opinion of the Committee for Orphan Medicinal Products of
the European Medicines Agency (EMEA), has granted orphan drug designation
to ambrisentan for the treatment of pulmonary arterial hypertension
(PAH) and chronic thromboembolic pulmonary hypertension.
The
information provided on the PHA website is provided for general information
only. It is not intended as legal, medical or other professional
advice, and should not be relied upon as a substitute for consultations
with qualified professionals who are familiar with your individual
needs.
On
July 4, 1999 our good friend Kipp Palmer passed away from complications
due to Primary Pulmonary Hypertension. Not only was Kipp a great golfer,
but he was a fighter who, in the end, couldn't prevail over PPH. Help
us remember Kipp on June 24th while contributing to the good cause
of PPH cure research.
